Northern Trust
AXSM icon

Northern Trust’s Axsome Therapeutics AXSM Stock Holding History

Northern Trust’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.9M Buy
401,459
+11,028
+3% +$1.9M 0.01% 934
2025
Q4 		$71.3M Sell
390,431
-19,104
-5% -$2.67M 0.01% 909
2025
Q3 		$49.7M Buy
409,535
+141
+0% +$15.9K 0.01% 1133
2025
Q2 		$42.7M Sell
409,394
-1,575
-0.4% -$167K 0.01% 1201
2025
Q1 		$47.9M Buy
410,969
+8,469
+2% +$965K 0.01% 1108
2024
Q4 		$34.1M Buy
402,500
+69,918
+21% +$6.43M ﹤0.01% 1370
2024
Q3 		$29.9M Buy
332,582
+8,089
+2% +$706K ﹤0.01% 1370
2024
Q2 		$26.1M Sell
324,493
-11,592
-3% -$858K ﹤0.01% 1389
2024
Q1 		$26.8M Sell
336,085
-7,223
-2% -$606K ﹤0.01% 1390
2023
Q4 		$27.3M Sell
343,308
-5,749
-2% -$384K ﹤0.01% 1398
2023
Q3 		$24.4M Buy
349,057
+22,916
+7% +$1.71M ﹤0.01% 1412
2023
Q2 		$23.4M Buy
326,141
+8,089
+3% +$597K ﹤0.01% 1480
2023
Q1 		$19.6M Buy
318,052
+6,107
+2% +$401K ﹤0.01% 1560
2022
Q4 		$24.1M Buy
311,945
+23,993
+8% +$1.43M 0.01% 1412
2022
Q3 		$12.8M Buy
287,952
+7,701
+3% +$385K ﹤0.01% 1807
2022
Q2 		$10.7M Sell
280,251
-458
-0.2% -$14.5K ﹤0.01% 1979
2022
Q1 		$11.6M Sell
280,709
-10,590
-4% -$328K ﹤0.01% 2054
2021
Q4 		$11M Buy
291,299
+14,049
+5% +$517K ﹤0.01% 2166
2021
Q3 		$9.14M Sell
277,250
-12,880
-4% -$502K ﹤0.01% 2345
2021
Q2 		$19.6M Sell
290,130
-14,292
-5% -$858K ﹤0.01% 1895
2021
Q1 		$17.2M Sell
304,422
-13,608
-4% -$957K ﹤0.01% 1935
2020
Q4 		$25.9M Sell
318,030
-34,703
-10% -$2.59M 0.01% 1620
2020
Q3 		$25.1M Sell
352,733
-22,506
-6% -$1.75M 0.01% 1453
2020
Q2 		$30.9M Buy
375,239
+19,741
+6% +$1.52M 0.01% 1276
2020
Q1 		$20.9M Buy
355,498
+22,931
+7% +$1.87M 0.01% 1366
2019
Q4 		$34.4M Sell
332,567
-580
-0.2% -$23.4K 0.01% 1292
2019
Q3 		$6.74M Buy
333,147
+242,884
+269% +$6.24M ﹤0.01% 2379
2019
Q2 		$2.33M Buy
90,263
+54,905
+155% +$1.1M ﹤0.01% 3000
2019
Q1 		$503K Buy
35,358
+4,843
+16% +$45K ﹤0.01% 3537
2018
Q4 		$86K Hold
30,515
– – ﹤0.01% 3954
2018
Q3 		$105K Hold
30,515
– – ﹤0.01% 4018
2018
Q2 		$97K Hold
30,515
– – ﹤0.01% 4025
2018
Q1 		$75K Sell
30,515
-3,477
-10% -$10.4K ﹤0.01% 4025
2017
Q4 		$190K Sell
33,992
-974
-3% -$4.92K ﹤0.01% 3831
2017
Q3 		$194K Hold
34,966
– – ﹤0.01% 3806
2017
Q2 		$192K Sell
34,966
-77,233
-69% -$323K ﹤0.01% 3806
2017
Q1 		$437K Buy
112,199
+6,966
+7% +$33.3K ﹤0.01% 3571
2016
Q4 		$711K Buy
105,233
+276
+0.3% +$1.94K ﹤0.01% 3441
2016
Q3 		$827K Buy
104,957
+83,265
+384% +$630K ﹤0.01% 3400
2016
Q2 		$164K Buy
+21,692
New +$200K ﹤0.01% 3769

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust's AXSM Position: Q1 2026 in Review

Northern Trust increased its Axsome Therapeutics (AXSM) stake by 2.8% in Q1 2026, buying an estimated $1.9M and bringing the position to 401,459 shares worth $67.9M. The position accounts for 0.01% of the portfolio, ranked #934.

Northern Trust first reported a position in AXSM in Q2 2016 and has held it in 40 quarters since. The position peaked at $71.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Northern Trust held 401,459 shares of Axsome Therapeutics worth $67.9M as of Q1 2026.
  • Northern Trust bought 11,028 Axsome Therapeutics shares in Q1 2026, an estimated $1.9M.
  • Axsome Therapeutics made up 0.01% of Northern Trust's portfolio in Q1 2026, its #934 holding.
  • Northern Trust first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Northern Trust's Axsome Therapeutics position peaked at $71.3M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.